Report

The Retinal Detachment Treatment market is projected to grow with a CAGR of nearly 3.3% over the forecast period.

The COVID-19 pandemic is expected to have a significant impact on the market in the short term. The lockdown measures worldwide resulted in decreased public mobility and impacted the healthcare industry. The lockdown all over the globe has affected the supply chain of pharmaceuticals, medical devices, and biotechnological products. Thus, it has affected the global retinal detachment treatment market to a certain extent. It is well recognized that front-line healthcare professionals are at a higher risk of contracting COVID-19. Because the eye surface and the nasopharyngeal mucosa, both of which express angiotensin-converting enzyme two (ACE2) receptors, are the exposed areas susceptible to infection, ophthalmologists are one of the three subspecialties with the highest risk of COVID-19 infection. As per the study "Emergency Retinal Detachment Surgery during Covid-19 Pandemic: a National Survey and Local Review" published in September 2020, in comparison to other specialties, ophthalmology has seen the highest decline in services during the COVID-19 pandemic. A survey analyzed whether the pandemic has affected vitreoretinal surgery in the United Kingdom. Results indicated that there was a reduction in retinal detachment diagnoses as a result of the lockdown. Researchers suggested that the COVID-19 outbreak and subsequent decisions on population lockdown may have had some impact on patient care.

Significant issues about access to eye care have arisen as a result of broad changes and limits to social and hygienic norms during the COVID-19 Pandemic. According to the EUROCOVAT group data published in February 2022, several national ophthalmology societies recommended limiting outpatient visits and deferring any treatment other than urgent or emergent care to prevent human-to-human viral transmission and divert resources to intensive care units, resulting in a significant reduction in the amount of care provided. Furthermore, as per the "Impact of COVID-19 Lockdown on Surgical Procedures for Retinal Detachment in France: a National Database Study" published in November 2021, when comparing 2019 and 2020, a nationwide medico-administrative database investigation revealed a 41.6% decrease in the total number of rhegmatogenous retinal detachment (RRD) surgical procedures performed in France during the 8-week COVID-19 shutdown. Therefore, measures regarding the COVID-19 outbreak and consequent population lockdown may have had some impact on patient care. As a result, it impacted the target market's growth throughout the pandemic and is anticipated to accelerate over the forecasted period.

The major factor attributing to the growth of the market is the increase in the geriatric population and the increasing incidence of diabetic retinopathy and other eye disorders. According to the article "At this World Diabetic Day, Let us Work Together to Combat Blindness due to Diabetic Retinopathy & Diabetes-Related Eye Problems" published in Open Access Journal of Ophthalmology in February 2021, India is deemed as the world's capital of diabetes. The diabetic population in the country is close to hitting the alarming mark of 69.9 million by 2025 and 80 million by 2030. The overall population affected by diabetes-related retinal disease is expected to cross the number of 592 million by 2025, and currently affecting nearly 18% of the diabetic population in India. Such data indicate that the market is expected to grow as more patient pool increase. However, the high cost of the procedures is expected to restrain the market during the forecast period.

Retinal Detachment Treatment Market Trends

Vitrectomy is the Fastest Growing Segment in the Market Studied Period

Vitrectomy is a surgical procedure undertaken by a specialist where the vitreous humor gel that fills the eye cavity is removed to provide better access to the retina. It allows for a variety of repairs, including the removal of scar tissue, laser repair of retinal detachments, and treatment of macular holes. After surgery saline, a gas bubble, or silicone oil may be injected into the vitreous gel to help hold the retina in position. Vitrectomy is an increasingly used treatment for retinal detachment. As per the study "Outcomes of Vitrectomy for Retinal Detachment in a Patient with Ehlers-Danlos Syndrome Type IV: a Case Report" published in the "Journal of Medical Case Reports" in May 2021, Small-gauge vitrectomy can prevent severe bleeding and lessen intraoperative trauma. Researchers concluded that high myopia retinal detachment in patients with EDS type IV can be successfully treated with small-gauge Pars plana vitrectomy (PPV). Hence, the demand for vitrectomy treatment is expected to increase, in turn, it is projected to aid the overall market growth during the forecast period.

Moreover, recent developments in transconjunctival pars plana vitrectomy instruments are expected to drive the segment growth. The advancements leads to fewer postoperative dry eye cases and conjunctival scars, more effective surgery, less postoperative inflammation leading to less discomfort and greater patient comfort, enhanced cosmetic results from surgery, fewer astigmatic alterations, and faster visual recovery. For instance, as per the article "Retinal Detachment Repair With Vitrectomy: Air Tamponade Integration to a Vitreoretinal Service, Comparison With Gas Tamponade, and Literature Review" published in the Journal of 'Ophthalmic Surg Lasers Imaging Retina in February 2022, the study concluded that in comparison to short-acting air tamponade, pars plana vitrectomy and gas tamponade (GT) restoration of rhegmatogenous retinal detachment (RRD) have significant clinical and quality-of-life effects.

As a result, all of the aforementioned factors are expected to contribute to this segment's strong growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market over the forecast period due to factors such as beneficial government initiatives and an increase in the number of research partnerships, the presence of key players, the high prevalence of diabetes-related complications in the region, the increasing geriatric population, and established healthcare infrastructure. For instance, according to the Centers for Disease Control and Prevention (CDC) data updated in May 2021, diabetic retinopathy is the most common cause of vision impairment and blindness among working-age adults in the United States. As per the same source, by 2050, the number of Americans with diabetic retinopathy is expected to reach 14.6 million. Hence, it is to expected to increase regional growth during the forecast period.

In this region, the United States holds the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. Also, a growing number of retina specialists will create lucrative opportunities in the country. For instance, in October 2021, Retina Consultants of America (RCA), a physician management services organization, added Tennessee Retina, which operates at nine locations such as Nashville, Bowling Green, and Crossville. The medical professionals at Tennessee Retina are involved in numerous regional, international, and local ophthalmologic and vitreoretinal professional societies. This collaboration will aid the expansion of retina specialists across the country.

As a result, all of the aforementioned reasons are likely to contribute to this region's strong growth over the forecast period.

Retinal Detachment Treatment Market Competitor Analysis

The Retinal Detachment Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are FCI Ophthalmics, Inami & CO., Ltd, Accurate Surgical & Scientific Instruments Corporation, Millennium Surgical Corp, and IRIDEX Corporation among others.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support